IRESSA was approved by the U.S. Food and Drug Administration on July 13, 2015 for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
TAGRISSO was approved by the U.S. Food and Drug Administration on November 13, 2015 for the treatment of patients with advanced NSCLC whose tumors have EGFR T790M mutation as detected by an FDA-approved test, and whose disease has gotten worse after treatment with other EGFR-blocking therapy.
In 2017, an estimated 222,500 new cases of lung cancer are expected in the U.S., according to the American Cancer Society. About 80 – 85 percent of lung cancers are NSCLC.
“At US Bioservices, our clinically integrated approach supports physicians by improving speed to therapy for their patients and providing streamlined workflows for the practice when working with a specialty pharmacy,” said Aaron Sathre, Senior Vice President of Client Growth and Development for US Bioservices. “It is this approach and our high-touch support for patients that allow us to best support IRESSA and TAGRISSO patients throughout their treatment plans.”
As an independent specialty pharmacy with a dedicated Oncology Patient Support Team, US Bioservices provides high-touch clinical care that is specific to the patient’s needs, conditions and therapies. US Bioservices’ multidisciplinary teams are organized to develop long-standing, collaborative relationships with oncologists, resulting in more integrated care for patients and caregivers.
IRESSA and TAGRISSO are limited distribution medications that are only available from select specialty pharmacies. Physicians may submit prescriptions to US Bioservices via phone (877.757.0667), fax (888.899.0067), ePrescribe or the MyPathpoint Prescriber Portal.
AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human and animal health. With over $140 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 19,000 people. AmerisourceBergen is ranked #12 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com